Australian cataract patients can now gain broader access to next-generation lens technology, after Rayner secured Medical Device and Human Tissue Advisory Committee (MDHTAC) acceptance and Prostheses List (PL) reimbursement for RayOne Galaxy, effective 1 March 2026.
In a media release, Rayner said its RayOne Galaxy, the world’s first spiral IOL, represented a significant advancement in premium lens replacement technology.
Developed with AI, its unique non-diffractive spiral optic delivers a smooth and continuous full range of vision with minimised dysphotopsia and 0% loss of transmitted light, it said.
Since its global launch in January 2025, RayOne Galaxy had demonstrated strong international clinical adoption, with over 90,000 lenses shipped worldwide.
The company said surgeons across multiple international markets had reported consistent refractive predictability, broad functional visual range, and high patient satisfaction in everyday clinical practice.
Real-world experience had been presented at leading international congresses, reinforcing confidence in the technology.
In parallel, a US clinical study conducted under an FDA-approved Investigational Device Exemption (IDE) confirmed favourable safety and effectiveness outcomes, with regulatory review in the United States ongoing.
Now, with PL reimbursement confirmed, privately insured cataract patients can access the Galaxy spiral lens without the additional out-of-pocket costs typically associated with non-listed lenses – an important step forward in expanding access to this advanced presbyopia-correcting technology.
Lisa Farquhar, Rayner’s country manager for Australia & New Zealand, said: “Galaxy was designed to redefine what’s possible – delivering a continuous range of vision without the trade-offs patients get with diffractive trifocal lenses.
“We are proud that this innovative technology will now be accessible to any privately insured patient in Australia, helping surgeons offer truly premium outcomes to more people than ever before.”
